Barclays raises Ionis stock price target on Tryngolza opportunity By Investing.com

Barclays raised its price target on Ionis to $106 (from $95) after modeling a $40,000 wholesale price for Tryngolza (down from $595,000) and boosting its 2034 U.S. revenue forecast for the drug to $4.0B. Ionis, valued at ~$12B, reported 34% revenue growth over the last 12 months but remains unprofitable with EPS of -$2.38 and the stock trading at $72.69. Multiple sell-side firms largely maintained or raised targets (RBC $95, BofA $100, Oppenheimer $104, Wolfe $97; Stifel $83 hold), indicating analysts view the aggressive price cut and uptake potential as a net positive for long-term revenue despite near-term margin implications.

Analysis

This pricing reset is a de facto admission that launch economics and payer access dynamics matter more to long‑term peak sales than headline list prices. Lower out‑of‑pocket expectations will materially expand the addressable patient population and shorten the ramp to meaningful volume, shifting the value driver from per‑unit margin to recurrence and share of treatment days over years.

Second‑order beneficiaries include specialty pharmacies and manufacturers of scalable oligonucleotide/ASO manufacturing capacity: higher volumes at lower per‑dose prices accelerate fixed‑cost absorption and compress COGS per treatment, improving gross margin contribution long term across the class. Conversely, entrants planning high‑list launches will face immediate pricing and contracting pressure; margin assumptions baked into competing launches and buyouts look vulnerable.

Near‑term catalysts that will re‑rate or reverse the setup are concrete payer coverage decisions, real‑world adherence data in the first 6–12 months, and any surprise post‑launch safety/regulatory actions. Tail risks include aggressive rebate demands from large payers, slower-than‑expected specialist adoption, or biosimilar/alternative modality entrants that alter lifetime revenue per patient over multi‑year horizons.

For portfolio construction, the right framing is optionality with defined downside: this is a commercialization execution and coverage call rather than a science call. Position sizing should reflect binary near‑term coverage outcomes (weeks–months) and multi‑year peak sales uncertainty, with active hedges keyed to payer/coding announcements.

Key Decisions for Investors

• Long IONS equity (size 1–2% NAV) with a Jan 2027 call spread to cap upside cost: buy 1y+ out‑of‑the‑money calls and sell higher strike calls. R/R: asymmetric upside if coverage ramps; limited funded downside via the spread if prescriber uptake lags.
• Buy IONS protective puts (3–6 month) for 0.5% NAV to hedge the equity leg against a catalyzing negative payer decision or safety headline. Cost is the insurance premium versus uninsured exposure to binary events.
• Pair trade: long IONS / short a broad biotech ETF or small‑cap peer (size net neutral) for 6–12 months to isolate commercialization/coverage upside while neutralizing sector beta. This reduces idiosyncratic risk from macro biotech selloffs.
• Avoid directional positions in BCS/OPY tied to analyst momentum; instead, use BCS as a tactical volatility play (short dated straddle if IV rich) around earnings/analyst days, and keep OPY as a watchlist for downstream exposure if class margins compress further.